H60 Antibody (205326) [Alexa Fluor™ Plus 488]

• Reactivity: Mu
• Clone: 205326
• Clonality: Monoclonal
• Host: Rat
• Conjugate: Alexa Fluor Plus 488

H60 Antibody (205326) [Alexa Fluor™ Plus 488] Summary

• Specificity: Detects mouse H60 in ELISAs and Western blots.
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Rat

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for H60 Antibody (205326) [Alexa Fluor™ Plus 488]

• H60
• H60a

Background

H60 was originally described as an immunodominant histocompatibility antigen that is expressed in BALB mice but not in B6 mice. More recently it was reported to function as a ligand for mouse NKG2D, an activating receptor found on NK cells, on some T cell subsets, and on stimulated macrophages. H60 shares approximately 25 percent amino acid identity with the Rae-1 family, a small group of proteins that also function as ligands for mouse NKG2D. H60 and the Rae-1 proteins are distantly related to MHC class I proteins, but they possesses only the alpha 1 and alpha 2 Ig-like domains, and have no capacity to bind peptide or interact with beta 2‑microglobulin. The genes encoding these proteins are not found within the Major Histocompatibility Complex on mouse chromosome 17, but rather map to mouse chromosome 10. Unlike the GPI-linked Rae-1 proteins, H60 appears to be anchored to the membrane via a hydrophobic transmembrane segment. H60 transcripts were found in embryonic tissue, in spleen, and in some transformed cell lines. Transcripts were also observed in mouse skin cells after exposure to carcinogens. Binding of H60 to NKG2D results in the activation of cytolytic activity and/or cytokine production by the NKG2D-expressing effector cells. Ectopic expression of H60 on mouse tumor cell lines resulted in the in vivo rejection of the tumors (1‑6).

1. Malarkannan, S. et al. (1998) J. Immunol. 161:3501.
2. Diefenbach, A. et al. (2000) Nature Immunol. 1:119.
3. Cerwenka, A. et al. (2000) Immunity 12:721.
4. Cerwenka, A. et al. (2001) Proc. Natl. Acad. Sci. USA 98:11521.
5. Diefenbach, A. et al. (2001) Nature 413:165.
6. NKG2D and its Ligands, www.RnDSystems.com.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.